Clinical Trial Update: Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) [Phase 3]

View source ↗

Summary

Phase 3 study evaluating a triple-antibody combination (SAR440340/REGN3500/itepekimab) for chronic obstructive pulmonary disease has completed. The update provi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• REGN3500 (anti-IL-33 monoclonal antibody)
• SAR440340 (anti-IL-33 monoclonal antibody)
• itepekimab (itepekimab)

Snippet

Sponsor: Sanofi | Conditions: Chronic Obstructive Pulmonary Disease | Phase 3 | Status: COMPLETED